[1]KALANTAR-ZADEH K, JAFAR T H, NITSCH D, et al.Chronic kidney disease[J].Lancet, 2021, 398(10302):786-802
[2]ROMAGNANI P, REMUZZI G, GLASSOCK R, et al.Chronic kidney disease[J].Nat Rev Dis Primers, 2017, 3(/):17088-17088
[3]FISHBANE S, COYNE D W.How I treat renal anemia[J].Blood, 2020, 136(7):783-789
[4]HIRANO I, SUZUKI N.The Neural Crest as the First Production Site of the Erythroid Growth Factor Erythropoietin[J].Front Cell Dev Biol, 2019, 7(7):105-105
[5]MC CAUSLAND F R, CLAGGETT B, BURDMANN E A, et al.Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)[J].Am J Kidney Dis, 2019, 73(3):309-315
[6]TANAKA T, NANGAKU M.Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents[J].Exp Cell Res, 2012, 318(9):1068-1073
[7]IWATA Y, SAKAI N, NAKAJIMA Y, et al.Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell[J].BMC Nephrol, 2021, 22(1):203-203
[8]KUPPE C, IBRAHIM M M, KRANZ J, et al.Decoding myofibroblast origins in human kidney fibrosis[J].Nature, 2021, 589(7841):281-286
[9]MIYATA T, SUZUKI N, VAN YPERSELE DE STRIHOU C.Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?[J].Kidney Int, 2013, 84(4):693-702
[10]SUZUKI N, YAMAMOTO M.Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis[J].Pflugers Arch, 2016, 468(1):3-12
[11]WU H, LIU X, JAENISCH R, et al.Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor[J].Cell, 1995, 83(1):59-67
[12]DAHL S L, PFUNDSTEIN S, HUNKELER R, et al.Fate-mapping of erythropoietin-producing cells in mouse models of hypoxaemia and renal tissue remodelling reveals repeated recruitment and persistent functionality[J].Acta Physiol (Oxf), 2022, /(/):e13768-e13768
[13]SOUMA T, YAMAZAKI S, MORIGUCHI T, et al.Plasticity of renal erythropoietin-producing cells governs fibrosis[J].J Am Soc Nephrol, 2013, 24(10):1599-1616
[14]SATO K, KUMAGAI N, SUZUKI N.Alteration of the DNA Methylation Signature of Renal Erythropoietin-Producing Cells Governs the Sensitivity to Drugs Targeting the Hypoxia-Response Pathway in Kidney Disease Progression[J]. Front Genet, 2019, 10(/):1134-1134
[15]SOUMA T, SUZUKI N, YAMAMOTO M.Renal erythropoietin-producing cells in health and disease[J].Front Physiol, 2015, 6(/):167-167
[16]SOUMA T, NEZU M, NAKANO D, et al.Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling[J].J Am Soc Nephrol, 2016, 27(2):428-438
[17]HUBBI M E, SEMENZA G L.Regulation of cell proliferation by hypoxia-inducible factors[J].Am J Physiol Cell Physiol, 2015, 309(12):C775-782
[18]SATO K, HIRANO I, SEKINE H, et al.An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts[J].Sci Rep, 2019, 9(1):11254-11254
[19]CHANG Y T, YANG C C, PAN S Y, et al.DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys[J].J Clin Invest, 2016, 126(2):721-731
[20]ANUSORNVONGCHAI T, NANGAKU M, JAO T M, et al.Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response[J].Kidney Int, 2018, 94(3):536-550
[21]LEE M, KIM S H, JHEE J H, et al.Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis[J].Stem Cell Res Ther, 2020, 11(1):422-422
[22]GENG X C, HU Z P, LIAN G Y.Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation[J].Mol Med Rep, 2015, 11(5):3860-3865
[23]LIN X, JIANG C, LUO Z, et al.Protective effect of erythropoietin on renal injury induced in rats by four weeks of exhaustive exercise[J].BMC Nephrol, 2013, 14(/):130-130
[24]LIU B, TAN P.PPAR gammaTLR4TGF-beta1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat[J].Ren Fail, 2020, 42(1):216-224
[25]VAZQUEZ-MENDEZ E, GUTIERREZ-MERCADO Y, MENDIETA-CONDADO E, et al.Recombinant Erythropoietin Provides Protection against Renal Fibrosis in Adenine-Induced Chronic Kidney Disease[J].Mediators Inflamm, 2020, 2020(1):1-11
[26]NOONAN M L, CLINKENBEARD E L, NI P, et al.Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)[J].Physiol Rep, 2020, 8(11):e14434-/
[27]BAHLMANN F H, SONG R, BOEHM S M, et al.Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure[J].Circulation, 2004, 110(8):1006-1012
[28]LI L, NAKANO D, ZHANG A, et al.Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice[J].J Pharmacol Sci, 2020, 144(4):229-236
[29]WAKASHIMA T, TANAKA T, FUKUI K, et al.JTZ-951,an HIF prolyl hydroxylase inhibitor,suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors[J].Am J Physiol Renal Physiol, 2020, 318(1):F14-F24
[30]GARRIDO P, RIBEIRO S, FERNANDES J, et al.Iron-hepcidin dysmetabolism,anemia and renal hypoxia,inflammation and fibrosis in the remnant kidney rat model[J].PLoS One, 2015, 10(4):e0124048-/
[31]RIBEIRO S, GARRIDO P, FERNANDES J, et al.Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia[J].Biochimie, 2016, 125(/):150-162
[32]OGINO A, TAKEMURA G, KAWASAKI M, et al.Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia[J].J Am Coll Cardiol, 2010, 56(23):1949-1958
[33]WU Y, YANG B.Erythropoietin Receptor/beta Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion[J].Front Immunol, 2021, 12(/):697796-697796
[34]FISCHER C, DEININGER N, WOLF G, et al.CERA Attenuates Kidney Fibrogenesis in the dbdb Mouse by Influencing the Renal Myofibroblast Generation[J].J Clin Med, 2018, 7(2):15-15
[35]SHI M, FLORES B, LI P, et al.Effects of erythropoietin receptor activity on angiogenesis,tubular injury,and fibrosis in acute kidney injury: a "U-shaped" relationship[J].Am J Physiol Renal Physiol, 2018, 314(4):F501-F516
[36]SULIKOWSKA B, RUTKOWSKI B, MARSZALEK A, et al.The role of interstitial changes in the progression of chronic kidney disease[J].Postepy Hig Med Dosw (Online), 2015, 69(/):830-837
[37]ACIKGOZ Y, CAN B, BEK K, et al.The effect of simvastatin and erythropoietin on renal fibrosis in rats with unilateral ureteral obstruction[J].Ren Fail, 2014, 36(2):252-257
[38]IZQUIERDO M C, SANZ A B, MEZZANO S, et al.TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation[J].Kidney Int, 2012, 81(11):1098-1107
[39]LIVINGSTON M J, DING H F, HUANG S, et al.Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction[J].Autophagy, 2016, 12(6):976-998
[40]ZHANG Y, ZHU X, HUANG X, et al.Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis[J].Front Med (Lausanne), 2020, 7(/):47-47
[41]ZHANG Y, WU Y, WANG W, et al.Long-Term Protection of CHBP Against Combinational Renal Injury Induced by Both Ischemia-Reperfusion and Cyclosporine A in Mice[J].Front Immunol, 2021, 12(/):697751-697751
[42]SENOUSY M A, HANAFY M E, SHEHATA N, et al.Erythropoietin and Bacillus Calmette-Guerin Vaccination Mitigate 3-Nitropropionic Acid-Induced Huntington-like Disease in Rats by Modulating the PI3K/Akt/mTOR/P70S6K Pathway and Enhancing the Autophagy[J].ACS Chem Neurosci, 2022, 13(6):721-732
[43]TSENG H C, LIN C C, HSIAO L D, et al.Lysophosphatidylcholine-induced mitochondrial fission contributes to collagen production in human cardiac fibroblasts[J].J Lipid Res, 2019, 60(9):1573-1589
[44]GUT N, PIECHA G, ALDEBSSI F, et al.Erythropoietin combined with ACE inhibitor prevents heart remodeling in 56 nephrectomized rats independently of blood pressure and kidney function[J].Am J Nephrol, 2013, 38(2):124-135
[45]TSUBAKIHARA Y, AKIZAWA T, IWASAKI M, et al.High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment[J].Ther Apher Dial, 2015, 19(5):457-465
[46]FUJITA Y, DOI Y, HAMANO T, et al.Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study[J].Sci Rep, 2019, 9(1):14871-14871
[47]GOBE G C, BENNETT N C, WEST M, et al.Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury[J].Am J Physiol Renal Physiol, 2014, 306(6):F681-F692
[48]PALMER S C, NAVANEETHAN S D, CRAIG J C, et al.Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease[J].Ann Intern Med, 2010, 153(1):23-33
[49]MODELLI DE ANDRADE L G, VIERO R M, CORDEIRO DE CARVALHO M F.Treatment of adriamycin-induced nephropathy with erythropoietin and G-CSF[J].J Nephrol, 2013, 26(3):534-539
[50]NOIRI E, NAGANO N, NEGISHI K, et al.Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats[J].Nephron Exp Nephrol, 2006, 104(1):e6-e14
